


Hepatitis C: State of Medicaid Access Report Card

Oklahoma



Grade	Recommendations to Improve Patient Access
F	<ul style="list-style-type: none"> Remove prior authorization for HCV treatment. Remove substance use counseling requirement. Remove specialty prescriber consultation requirement. Remove retreatment restrictions. Remove additional restrictions as described below.

State Overview

As of February 2022, 1,160,088 individuals were enrolled in Medicaid and CHIP.¹ It is estimated that as of 2016, 53,300 people were living with HCV in Oklahoma.² Oklahoma Medicaid does not contract with any managed care organizations (MCOs).

The Oklahoma Medicaid Preferred Drug List includes sofosbuvir/velpatasvir and Mavyret.³

Deductions		Policy				
Prior Authorization	-8	Prior authorization is required for all Direct-Acting Antiviral (DAA) HCV treatment regimens. ⁴				
Fibrosis Restrictions	0	Oklahoma Medicaid does not impose fibrosis restrictions. ⁵				
Substance Use Restrictions	-12	Oklahoma Medicaid imposes substance use restrictions. Prescribers are required to “counsel members on potential harms of illicit IV drug use or alcohol use and member must agree to no illicit IV drug use or alcohol use while on treatment and post-therapy.” ⁶				
Prescriber Restrictions	-8	Oklahoma Medicaid imposes prescriber restrictions. HCV treatment may only be prescribed by a “gastroenterologist, infectious disease specialist, or transplant specialist or the member must have been evaluated for hepatitis C treatment by a gastroenterologist, infectious disease specialist, or transplant specialist within the last three months.” ⁷				
Retreatment Restrictions	-8	Oklahoma Medicaid imposes retreatment restrictions. Failure to adhere to strict compliance policies during previous treatment regimen may be used to limit retreatment access. ⁸				
Access in Managed Care	0	Oklahoma does not contract with MCOs. ⁹				
Additional Restrictions	-8	Oklahoma Medicaid imposes additional restrictions as follows: ¹⁰ <ul style="list-style-type: none"> HCV RNA test must be collected within the last 12 months (when fibrosis \geqF1); or HCV antibody test and HCV RNA test must be collected within the last 3 months, or 2 HCV RNA tests must be collected at least 6 months apart (when fibrosis <F1). Confirmation of chronic HCV infection. Documentation of genotype. Documentation of adherence agreement. Patients have to complete a 'Hepatitis C Therapy Intent to Treat Contract' that states if a patient misses treatment for more than 3 days a month, their medication will no longer be paid for. 				
Total Deductions	-44	<table border="1" style="width: 100%; text-align: center;"> <tr> <td>Total Score [100-Deductions]</td> <td>Grade</td> </tr> <tr> <td>56</td> <td>F</td> </tr> </table>	Total Score [100-Deductions]	Grade	56	F
Total Score [100-Deductions]	Grade					
56	F					

Contact Your State Officials

Medicaid Office¹¹: Traylor Rains, Medicaid Director, Oklahoma Health Care Authority, State of Oklahoma
4345 North Lincoln Blvd., Oklahoma City, OK 73105; Telephone: (405) 522-7300

Key Sources

Clinical Criteria: [Oklahoma Health Care Authority, Prior Authorization \(Apr. 2022\)](#).

Hepatitis C Therapy Intent to Treat Contract: [Oklahoma Health Care Authority, Hepatitis C Therapy Intent to Treat Contract \(Dec. 2021\)](#).

¹ Centers for Medicare & Medicaid Services, Medicaid & CHIP in Oklahoma: <https://perma.cc/UCQ6-6DNC>.

² HepVu, Local Data: Oklahoma (Jan. 2022): <https://perma.cc/D8WT-FWWG>.

³ Clinical Criteria.

⁴ Clinical Criteria.

⁵ Clinical Criteria.

⁶ Oklahoma Health Care Authority, Hepatitis C Therapy Intent to Treat Contract.

⁷ Clinical Criteria.

⁸ Clinical Criteria.

⁹ Kaiser Family Foundation, Share of Medicaid Population Covered Under Different Delivery Systems (July 1, 2021): <https://perma.cc/SY4K-FFQ5>.

¹⁰ Clinical Criteria.

¹¹ National Association of Medicaid Directors, Medicaid Directors: <https://perma.cc/RK6K-TFKK>.